Synapse - Works

Results (116158)

Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)

Meeting Abstract

Friedlander, M. L.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer

Meeting Abstract

Gartrell, B.; Del Priore, G.; Retter, A.; Chen, W. T.; Sokol, G. H.; Vandell, A.; Roach, M.; Scher, H. I.
Annals of Oncology (2019)

Fulltext@MSK | Save

The influence of TDM on achieving busulfan target exposure and related determinants, in both children and adults who underwent an allogeneic hematopoietic cell transplantation

Meeting Abstract

Boss, J.; Langenhorst, J.; Lalmohamed, A.; van der Linden, P.; Boelens, J. J.; Van Maarseveen, E.
Annals of Oncology (2019)

Fulltext@MSK | Save

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

Meeting Abstract

Chi, K. N.; Rathkopf, D.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Sieber, P.; Dunshee, C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Meeting Abstract

de Wit, R.; Kulkarni, G. S.; Uchio, E.; Boormans, J. L.; Roumiguie, M.; Krieger, L. E. M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies

Meeting Abstract

Diaz, L. A.; Le, D.; Maio, M.; Ascierto, P. A.; Geva, R.; Motola-Kuba, D.; André, T.; Van Cutsem, E.; Gottfried, M.; Elez, E.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Randomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer

Meeting Abstract

Banerjee, S.; Vergotte, I.; Colombo, N.; Barve, M.; Grisham, R.; Mehr, K. T.; Falk, M.; Beier, F.; Hennessy, M.; Schroeder, A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): Characterization of hepatic adverse reactions (ARs)

Meeting Abstract

Bauer, S.; Lewis, J. H.; Gelderblom, H.; van de Sande, M.; Stacchiotti, S.; Healey, J. H.; Tap, W. D.; Wagner, A. J.; Pousa, A. L.; Druta, M.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

A phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)

Meeting Abstract

Bendell, J.; Lieu, C.; Raghav, K. P. S.; Argilés, G.; Cubillo, A.; Qu, X.; Yan, Y.; Merchant, M.; Zeuner, H.; Gallo, J. D.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results

Meeting Abstract

Borazanci, E.; Schram, A.; Brana, I.; Vieito Villar, M.; Garralda, E.; Spreafico, A.; Oliva, M.; Lakhani, N.; Wasserman, R.; Hoffman, K.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save